Lipum is member of the consortium together with both industry and academic partners. The project is led by the Cardiovascular Research Centre (CVRC) at Örebro University that was granted 10 million SEK from the Swedish Knowledge foundation (KKS). The total project budget is at least 26.9 million SEK and the other partners primarily provide materials and in-kind contributions. The project will start during 2022.
"We are already involved in a previous project and have a rewarding collaboration with the Cardiovascular Research Center. This new grant provides continued opportunities for the research collaboration, and it is fully in line with our plan to study additional indications for our drug candidate SOL-116", says CEO Einar Pontén
Swedish Knowledge foundation (KKS) funds research and competence development at Sweden’s university colleges and new universities with the purpose of strengthening Sweden’s competitiveness.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 5783495
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: email@example.com, phone: +46 8 503 000 50.